MAPT and tauopathy: After establishing the initiation and spread of tau pathology following intracortical injections of AAV‐2×Tau, we investigated both CSF biomarkers and in vivo imaging to assess the extent to which clinically relevant tools can reflect tauopathy progression in our NHP model.